Sierra Oncology
1820 Gateway Drive
Suite 110
San Mateo
California
94404
United States
Tel: 650-376-8679
Website: https://sierraoncology.com/
About Sierra Oncology
194 articles about Sierra Oncology
-
Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts
12/7/2020
--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count--
-
Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting
12/5/2020
Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib
-
Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH
12/1/2020
--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian , Ruben Mesa and Srdan Verstovsek--
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11/25/2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan
-
Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference
11/12/2020
- Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced that President and Chief Executive Officer Stephen Dilly , MBBS, PhD, will present an
-
Sierra Oncology to Report Momelotinib Long-term Overall Survival Data in Oral Presentation at ASH 2020
11/5/2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced two abstracts have been selected for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting being held December 5-8, 2020.
-
Sierra Oncology Reports Third Quarter 2020 Results
11/5/2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today
-
Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020
10/2/2020
Sierra Oncology, Inc. granted stock options to two new employees, as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
Sierra to Present at September Investor Conferences
9/14/2020
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis, today announced that Dr. Stephen Dilly , President and CEO, will present an overview of the company at two investor conference
-
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib
8/6/2020
Sierra Oncology, Inc. announced the appointments of Mr. Kevin Norrett as Chief Business Officer and Mr. William D. Turner as Chief Regulatory and Technical Operations Officer.
-
Sierra Oncology Reports Second Quarter 2020 Results
8/6/2020
Sierra Oncology, Inc.today reported its financial and operational results for the second quarter ended June 30, 2020.
-
Sierra Oncology Appoints Christina Thomson as General Counsel
7/28/2020
- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company -.
-
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
6/12/2020
Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib
-
Sierra Oncology Announces Presentations at Upcoming Investor Conferences - May 27, 2020
5/27/2020
Sierra Oncology, Inc. announced that Dr. Barbara Klencke, Chief Development Officer, will present the company at the upcoming Jefferies Global Virtual Healthcare Conference and at the Oppenheimer Biotech by the Lake 2020 Investor Summit.
-
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
5/26/2020
Sierra Oncology, Inc., a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced the appointment of Dr. Stephen Dilly as President and Chief Executive Officer, effective June 1, 2020.
-
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress
5/14/2020
Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity - - Long-term safety profile reinforces lack of emergent or cumulative toxicity with extended daily momelotinib administration - VANCOUVER , May 14, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development
-
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
5/7/2020
Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th
-
Sierra Oncology Reports First Quarter 2020 Results
5/7/2020
Sierra Oncology, Inc. (SRRA), today reported its financial and operational results for the first quarter ending March 31 2020
-
Sierra Oncology Reports 2019 Year End Results
3/3/2020
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today reported its financial and operational results for the year ended December 31, 2019.
-
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call
2/26/2020
VANCOUVER , Feb. 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released on Tuesda